When and How to Treat Chronic Lymphocytic Leukemia
- 14 December 2000
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 343 (24) , 1799-1801
- https://doi.org/10.1056/nejm200012143432410
Abstract
Chronic lymphocytic leukemia (CLL), the most common form of leukemia in adults, is usually recognized first by the patient's primary care physician. When the patient has other medical problems — which is frequently the case, given that the median age at diagnosis is 64 years — the primary care physician collaborates with the hematologist or oncologist in treating the patient. It is often difficult to make decisions about therapy, which can involve subtle factors that are best understood by the patient's own doctor.CLL most commonly arises from a malignant clone of B cells with a characteristic phenotype. It is . . .Keywords
This publication has 9 references indexed in Scilit:
- Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2000
- Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic LeukemiaBlood, 1999
- Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic LeukemiaBlood, 1999
- Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized TrialsJNCI Journal of the National Cancer Institute, 1999
- Chlorambucil in Indolent Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 1998
- Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemiaThe Lancet, 1996
- The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoireImmunology Today, 1994
- A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysisCancer, 1981
- Clinical staging of chronic lymphocytic leukemiaBlood, 1975